{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-071801","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.347375+00:00","generated_at":"2026-06-01T04:24:00.127966+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gain Therapeutics prices $11M public offering of common stock and pre-funded warrants","bullets":["Offering of 7,116,547 shares at $1.35/share and 1,031,602 pre-funded warrants at $1.3499 each.","Gross proceeds of ~$11M; net proceeds of ~$10.1M after discounts and expenses.","Proceeds to fund clinical development of GT-02287 for GBA1 Parkinson's disease.","Underwriter Titan Partners granted 30-day option for 1,222,222 additional shares (15% over-allotment).","Underwriter warrants for 570,370 shares at $1.6875, exercisable 6 months post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-071801","json":"https://secwatch.observer/filing/0001104659-24-071801.json","markdown":"https://secwatch.observer/filing/0001104659-24-071801.md","text":"https://secwatch.observer/filing/0001104659-24-071801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924071801/0001104659-24-071801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924071801/tm2416858d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:24:00.127966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}